Molecular markers and mortality in prostate cancer

BJU International

Volumn 100, Issue 6, 2007, Pages 1259-1263

  Concato, John ^a,b   Jain, Dhanpat ^b   Li, William W ^c   Risch, Harvey A ^b   Uchio, Edward M ^b   Wells, Carolyn K ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The Angiogenesis Foundation   (United States)

Author keywords

Angiogenesis; bcl 2 proto oncogene; Prognosis; Prostatic neoplasms

Indexed keywords

MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LABORATORY TEST; MALE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; MICROVASCULATURE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STAINING; TUMOR BIOPSY; UNITED STATES; VETERAN;

AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 35748949238     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07136.x     Document Type: Article

References (23)

1. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001 58 : 843 8
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
3. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
4. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7
5. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995 274 : 626 31
6. Ross JS, Sheehan CE, Dolen EM, Kallakury BVS. Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002 9 : 115 28
7. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005 41 : 858 87
8. Concato J, Wells CK, Horwitz RI et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 2006 166 : 38 43
9. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: Alternatives to the National Death Index. Am J Epidemiol 1995 141 : 242 50
10. Stampfer MJ, Willett WC, Speizer FE et al. Tests of the National Death Index. Am J Epidemiol 1984 119 : 837 9
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987 40 : 373 83
12. Trikha M, Raso E, Cai Y et al. Role of alphaII (b) beta3 integrin in prostate cancer metastasis. Prostate 1998 35 : 185 92
13. Ferrer FA, Miller LJ, Andrawis RI et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997 157 : 2329 33
14. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995 55 : 4438 45
15. Quinn D, Henshall S, Head D et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000 60 : 1585 94
16. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res 2000 20 : 3791 9
17. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models. Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 : 361 87
18. Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993 72 : 3131 5
19. Concato J. Challenges in prognostic analysis. Cancer 2001 91 (Suppl. 1607 14
20. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J General Intern Med 2000 15 : 694 701
21. Shariat SF, Lotan Y, Saboorian H et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004 100 : 751 7
22. Barry MJ, Albertsen PC, Bagshaw MA et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001 91 : 2302 14
23. Wong Y-N, Mitra N, Hudes G et al. Survival associated with treatment vs. observation of localized prostate cancer in elderly men. JAMA 2006 296 : 2683 93